Recent News

• 04.08.2025 - ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025
• 04.07.2025 - ImmuCell Hires Chief Financial Officer
• 04.02.2025 - ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®
• 02.25.2025 - ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
• 02.20.2025 - ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
• 01.16.2025 - ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses
• 01.09.2025 - ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024
• 01.09.2025 - ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024

Recent Filings

• 04.08.2025 - EX-99.1 EX-99.1
• 04.08.2025 - 8-K Current report
• 04.07.2025 - 8-K Current report
• 04.07.2025 - EX-99.1 EX-99.1
• 04.07.2025 - 3 Initial statement of beneficial ownership of securities
• 03.28.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.25.2025 - EX-99.1 EX-99.1
• 02.25.2025 - 8-K Current report
• 01.16.2025 - EX-99.1 EX-99.1
• 01.16.2025 - 8-K Current report